Ibrutinib-rituximab ‘new standard of care’ in younger CLL patientsDecember 11, 2018Aggressive Lymphomas
Phase 3 study confirms biosimilarity of PF-05280586 with rituximabDecember 5, 2018Aggressive Lymphomas
FLYER: R-CHOP 4 safer, as effective for low-risk DLBCL patients under 60December 1, 2018Aggressive Lymphomas
CNS lymphoma guidelines stress patient fitness, not age, in choosing treatmentNovember 30, 2018Aggressive Lymphomas
